


Big advances in kidney care come at a **molecular** level.



## Molecular-level insights for optimized care.

**Customized care can improve health outcomes — but it requires deeper insights.**

That's where Natera comes in. With Natera's precise DNA analysis, you can effectively manage and provide the best available care to all your kidney patients.

Seeking the full picture?

**Renasight™**  
Kidney gene panel

**Integrate DNA technology for better patient care.** Up to 36% of all adult-onset cases have an undiagnosed cause.<sup>1</sup>



**See more. Know more with Renasight.**

Leverage next-gen sequencing on 380+ genes linked to CKD.



Want more precise post-transplant assessments?

**Prospera™**  
Transplant assessment

**A comprehensive view of your patient's rejection status.** Providers could improve their post-transplant rejection assessments by more than 50%.<sup>3</sup>



**Prospera offers more precise solutions for post-transplant rejection assessment.**

With a 95% negative predictive value, Prospera misses ~3x fewer rejections than serum creatinine.<sup>4</sup>

**~3x**

Contact us to see how Natera's molecular innovations can help you give your patients the care they deserve.

<https://www.natera.com/organ-health/>

**References:**

1. Connaughton D and Hildebrandt F. Nephrol Dial Transplant (2019) 1 8.
2. Groopman EE, Marasa M, Cameron-Christie S, et al. Diagnostic utility of exome sequencing for kidney disease. NEJM. 2018;doi:10.1056.
3. Peabody, et al. Randomized clinical utility trial of a novel donor-derived cfDNA test to detect rejection in CPV-simulated renal post-transplant patients. International Urology and Nephrology. 2020;doi.org/10.1007/s11255-020-02491-1.
4. Sigdel TK, Archila FA, Constantin T, et al. Optimizing detection of kidney transplant injury by assessment of donor-derived cell-free DNA via massively multiplex PCR. J Clin Med. 2019;8(1):19.